This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IUdR/BUdR Cell Cycle Labelling

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: July 24, 2002
Last updated: January 20, 2012
Last verified: January 2012
To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Condition Intervention
Hematologic Malignancies Drug: Chemotherapy for hematologic malignancy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Further study details as provided by M.D. Anderson Cancer Center:

Enrollment: 28
Study Start Date: May 1992
Study Completion Date: October 2002
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
Detailed Description:
Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Histologic proof of one of:

  • AML, ALL, or AUL
  • MDS or CMML
  • CML
  • OR undergoing bone marrow transplantation.

Participants should be:

  • off therapy for at least two weeks
  • At least 18 years old or older
  • Using adequate contraception if of child-bearing capability.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00042250

United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Study Chair: Michael Andreeff, MD, PhD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00042250     History of Changes
Other Study ID Numbers: DM91-102
Study First Received: July 24, 2002
Last Updated: January 20, 2012

Keywords provided by M.D. Anderson Cancer Center:
Cell Cycle Interphase
S Phase

Additional relevant MeSH terms:
Neoplasms processed this record on June 23, 2017